Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Jan;95(1):350–359. doi: 10.1172/JCI117663

Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function.

E Verpy 1, E Couture-Tosi 1, E Eldering 1, M Lopez-Trascasa 1, P Späth 1, T Meo 1, M Tosi 1
PMCID: PMC295438  PMID: 7814636

Abstract

The last exon of the C1-1NH gene was screened for point mutations in 36 unrelated hereditary angioedema patients. Mutations were found in eight patients, predicting changes in the short COOH-terminal region which anchors the reactive site loop on its COOH-terminal side. The effects of each of these mutations were examined in transiently transfected Cos-7 cells. Complete intracellular retention or degradation was observed with substitutions in the COOH-terminal strands 4B or 5B: Leu459-->Pro, Leu459-->Arg, and Pro467-->Arg were all blocked at early stages of intracellular transport, but differences in the immunofluorescence patterns indicated that a significant fraction of the Leu459-->Pro and of the Pro467-->Arg proteins reached a compartment distinct from the endoplasmic reticulum. In line with previous findings with alpha 1-antitrypsin, chain termination within strand 5B resulted in rapid degradation. Mutant Val451-->Met, in strand 1C, and mutant Pro476-->Ser, replacing the invariant proline near the COOH terminus, yielded reduced secretion, but these extracellular proteins were unable to bind the target protease C1s. Presence of low levels of both dysfunctional proteins in patient plasmas defies the conventional classification of C1 inhibitor deficiencies as type I or type II. These data point to a key role of certain residues in the conserved COOH-terminal region of serpins in determining the protein foldings compatible with transport and proper exposure of the reactive site loop.

Full text

PDF
350

Images in this article

351Image
on p.351
353Image
on p.353
353Image
on p.353
353Image
on p.353
354Image
on p.354
355Image
on p.355

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amara J. F., Lederkremer G., Lodish H. F. Intracellular degradation of unassembled asialoglycoprotein receptor subunits: a pre-Golgi, nonlysosomal endoproteolytic cleavage. J Cell Biol. 1989 Dec;109(6 Pt 2):3315–3324. doi: 10.1083/jcb.109.6.3315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Amitay R., Shachar I., Rabinovich E., Haimovich J., Bar-Nun S. Degradation of secretory immunoglobulin M in B lymphocytes occurs in a postendoplasmic reticulum compartment and is mediated by a cysteine protease. J Biol Chem. 1992 Oct 15;267(29):20694–20700. [PubMed] [Google Scholar]
  3. Aulak K. S., Cicardi M., Harrison R. A. Identification of a new P1 residue mutation (444Arg----Ser) in a dysfunctional C1 inhibitor protein contained in a type II hereditary angioedema plasma. FEBS Lett. 1990 Jun 18;266(1-2):13–16. doi: 10.1016/0014-5793(90)81494-9. [DOI] [PubMed] [Google Scholar]
  4. Aulak K. S., Eldering E., Hack C. E., Lubbers Y. P., Harrison R. A., Mast A., Cicardi M., Davis A. E., 3rd A hinge region mutation in C1-inhibitor (Ala436-->Thr) results in nonsubstrate-like behavior and in polymerization of the molecule. J Biol Chem. 1993 Aug 25;268(24):18088–18094. [PubMed] [Google Scholar]
  5. Aulak K. S., Pemberton P. A., Rosen F. S., Carrell R. W., Lachmann P. J., Harrison R. A. Dysfunctional C1-inhibitor(At), isolated from a type II hereditary-angio-oedema plasma, contains a P1 'reactive centre' (Arg444----His) mutation. Biochem J. 1988 Jul 15;253(2):615–618. doi: 10.1042/bj2530615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bissler J. J., Donaldson V. H., Davis A. E., 3rd Contiguous deletion and duplication mutations resulting in type 1 hereditary angioneurotic edema. Hum Genet. 1994 Mar;93(3):265–269. doi: 10.1007/BF00212020. [DOI] [PubMed] [Google Scholar]
  7. Bock S. C., Skriver K., Nielsen E., Thøgersen H. C., Wiman B., Donaldson V. H., Eddy R. L., Marrinan J., Radziejewska E., Huber R. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry. 1986 Jul 29;25(15):4292–4301. doi: 10.1021/bi00363a018. [DOI] [PubMed] [Google Scholar]
  8. Brodbeck R. M., Brown J. L. Secretion of alpha-1-proteinase inhibitor requires an almost full length molecule. J Biol Chem. 1992 Jan 5;267(1):294–297. [PubMed] [Google Scholar]
  9. Carrell R. W., Owen M. C. Plakalbumin, alpha 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. Nature. 1985 Oct 24;317(6039):730–732. doi: 10.1038/317730a0. [DOI] [PubMed] [Google Scholar]
  10. Carter P. E., Dunbar B., Fothergill J. E. Genomic and cDNA cloning of the human C1 inhibitor. Intron-exon junctions and comparison with other serpins. Eur J Biochem. 1988 Apr 5;173(1):163–169. doi: 10.1111/j.1432-1033.1988.tb13980.x. [DOI] [PubMed] [Google Scholar]
  11. Carter P. E., Duponchel C., Tosi M., Fothergill J. E. Complete nucleotide sequence of the gene for human C1 inhibitor with an unusually high density of Alu elements. Eur J Biochem. 1991 Apr 23;197(2):301–308. doi: 10.1111/j.1432-1033.1991.tb15911.x. [DOI] [PubMed] [Google Scholar]
  12. Cooper N. R. The classical complement pathway: activation and regulation of the first complement component. Adv Immunol. 1985;37:151–216. doi: 10.1016/s0065-2776(08)60340-5. [DOI] [PubMed] [Google Scholar]
  13. Cotton R. G., Rodrigues N. R., Campbell R. D. Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations. Proc Natl Acad Sci U S A. 1988 Jun;85(12):4397–4401. doi: 10.1073/pnas.85.12.4397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Crystal R. G. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest. 1990 May;85(5):1343–1352. doi: 10.1172/JCI114578. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Cugno M., Nuijens J., Hack E., Eerenberg A., Frangi D., Agostoni A., Cicardi M. Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema. J Clin Invest. 1990 Apr;85(4):1215–1220. doi: 10.1172/JCI114555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Davis A. E., 3rd, Aulak K., Parad R. B., Stecklein H. P., Eldering E., Hack C. E., Kramer J., Strunk R. C., Bissler J., Rosen F. S. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. Nat Genet. 1992 Aug;1(5):354–358. doi: 10.1038/ng0892-354. [DOI] [PubMed] [Google Scholar]
  17. Davis A. E., 3rd C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol. 1988;6:595–628. doi: 10.1146/annurev.iy.06.040188.003115. [DOI] [PubMed] [Google Scholar]
  18. Eldering E., Huijbregts C. C., Lubbers Y. T., Longstaff C., Hack C. E. Characterization of recombinant C1 inhibitor P1 variants. J Biol Chem. 1992 Apr 5;267(10):7013–7020. [PubMed] [Google Scholar]
  19. Eldering E., Nuijens J. H., Hack C. E. Expression of functional human C1 inhibitor in COS cells. J Biol Chem. 1988 Aug 25;263(24):11776–11779. [PubMed] [Google Scholar]
  20. Esser V., Russell D. W. Transport-deficient mutations in the low density lipoprotein receptor. Alterations in the cysteine-rich and cysteine-poor regions of the protein block intracellular transport. J Biol Chem. 1988 Sep 15;263(26):13276–13281. [PubMed] [Google Scholar]
  21. Frangi D., Aulak K. S., Cicardi M., Harrison R. A., Davis A. E., 3rd A dysfunctional C1 inhibitor protein with a new reactive center mutation (Arg-444-->Leu). FEBS Lett. 1992 Apr 13;301(1):34–36. doi: 10.1016/0014-5793(92)80204-t. [DOI] [PubMed] [Google Scholar]
  22. Frangi D., Cicardi M., Sica A., Colotta F., Agostoni A., Davis A. E., 3rd Nonsense mutations affect C1 inhibitor messenger RNA levels in patients with type I hereditary angioneurotic edema. J Clin Invest. 1991 Sep;88(3):755–759. doi: 10.1172/JCI115373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Gardner A. M., Aviel S., Argon Y. Rapid degradation of an unassembled immunoglobulin light chain is mediated by a serine protease and occurs in a pre-Golgi compartment. J Biol Chem. 1993 Dec 5;268(34):25940–25947. [PubMed] [Google Scholar]
  24. Grompe M., Muzny D. M., Caskey C. T. Scanning detection of mutations in human ornithine transcarbamoylase by chemical mismatch cleavage. Proc Natl Acad Sci U S A. 1989 Aug;86(15):5888–5892. doi: 10.1073/pnas.86.15.5888. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Higuchi R., Krummel B., Saiki R. K. A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res. 1988 Aug 11;16(15):7351–7367. doi: 10.1093/nar/16.15.7351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Hsu V. W., Shah N., Klausner R. D. A brefeldin A-like phenotype is induced by the overexpression of a human ERD-2-like protein, ELP-1. Cell. 1992 May 15;69(4):625–635. doi: 10.1016/0092-8674(92)90226-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Huber R., Carrell R. W. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry. 1989 Nov 14;28(23):8951–8966. doi: 10.1021/bi00449a001. [DOI] [PubMed] [Google Scholar]
  28. Jochmans K., Lissens W., Vervoort R., Peeters S., De Waele M., Liebaers I. Antithrombin-Gly 424 Arg: a novel point mutation responsible for type 1 antithrombin deficiency and neonatal thrombosis. Blood. 1994 Jan 1;83(1):146–151. [PubMed] [Google Scholar]
  29. Kornfeld R., Kornfeld S. Comparative aspects of glycoprotein structure. Annu Rev Biochem. 1976;45:217–237. doi: 10.1146/annurev.bi.45.070176.001245. [DOI] [PubMed] [Google Scholar]
  30. Kramer J., Katz Y., Rosen F. S., Davis A. E., 3rd, Strunk R. C. Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema. J Clin Invest. 1991 May;87(5):1614–1620. doi: 10.1172/JCI115175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Lane D. A., Olds R. J., Conard J., Boisclair M., Bock S. C., Hultin M., Abildgaard U., Ireland H., Thompson E., Sas G. Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest. 1992 Dec;90(6):2422–2433. doi: 10.1172/JCI116133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Lau M. M., Neufeld E. F. A frameshift mutation in a patient with Tay-Sachs disease causes premature termination and defective intracellular transport of the alpha-subunit of beta-hexosaminidase. J Biol Chem. 1989 Dec 15;264(35):21376–21380. [PubMed] [Google Scholar]
  33. Le A., Graham K. S., Sifers R. N. Intracellular degradation of the transport-impaired human PiZ alpha 1-antitrypsin variant. Biochemical mapping of the degradative event among compartments of the secretory pathway. J Biol Chem. 1990 Aug 15;265(23):14001–14007. [PubMed] [Google Scholar]
  34. Levy N. J., Ramesh N., Cicardi M., Harrison R. A., Davis A. E., 3rd Type II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1 inhibitor gene. Proc Natl Acad Sci U S A. 1990 Jan;87(1):265–268. doi: 10.1073/pnas.87.1.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Lippincott-Schwartz J., Bonifacino J. S., Yuan L. C., Klausner R. D. Degradation from the endoplasmic reticulum: disposing of newly synthesized proteins. Cell. 1988 Jul 15;54(2):209–220. doi: 10.1016/0092-8674(88)90553-3. [DOI] [PubMed] [Google Scholar]
  36. Loebermann H., Tokuoka R., Deisenhofer J., Huber R. Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol. 1984 Aug 15;177(3):531–557. [PubMed] [Google Scholar]
  37. Nuijens J. H., Eerenberg-Belmer A. J., Huijbregts C. C., Schreuder W. O., Felt-Bersma R. J., Abbink J. J., Thijs L. G., Hack C. E. Proteolytic inactivation of plasma C1- inhibitor in sepsis. J Clin Invest. 1989 Aug;84(2):443–450. doi: 10.1172/JCI114185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Olds R. J., Lane D. A., Caso R., Panico M., Morris H. R., Sas G., Dawes J., Thein S. L. Antithrombin III Budapest: a single amino acid substitution (429Pro to Leu) in a region highly conserved in the serpin family. Blood. 1992 Mar 1;79(5):1206–1212. [PubMed] [Google Scholar]
  39. Ou W. J., Cameron P. H., Thomas D. Y., Bergeron J. J. Association of folding intermediates of glycoproteins with calnexin during protein maturation. Nature. 1993 Aug 26;364(6440):771–776. doi: 10.1038/364771a0. [DOI] [PubMed] [Google Scholar]
  40. Parad R. B., Kramer J., Strunk R. C., Rosen F. S., Davis A. E., 3rd Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6786–6790. doi: 10.1073/pnas.87.17.6786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Quastel M., Harrison R., Cicardi M., Alper C. A., Rosen F. S. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest. 1983 Apr;71(4):1041–1046. doi: 10.1172/JCI110831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. ROSEN F. S., PENSKY J., DONALDSON V., CHARACHE P. HEREDITARY ANGIONEUROTIC EDEMA: TWO GENETIC VARIANTS. Science. 1965 May 14;148(3672):957–958. doi: 10.1126/science.148.3672.957. [DOI] [PubMed] [Google Scholar]
  43. Salerno G., Verde P., Nolli M. L., Corti A., Szöts H., Meo T., Johnson J., Bullock S., Cassani G., Blasi F. Monoclonal antibodies to human urokinase identify the single-chain pro-urokinase precursor. Proc Natl Acad Sci U S A. 1984 Jan;81(1):110–114. doi: 10.1073/pnas.81.1.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Siddique Z., McPhaden A. R., Fothergill J. E., Whaley K. A point mutation in the C1-inhibitor gene causes type I hereditary angiooedema. Hum Hered. 1993 May-Jun;43(3):155–158. doi: 10.1159/000154171. [DOI] [PubMed] [Google Scholar]
  45. Siddique Z., McPhaden A. R., McCluskey D., Whaley K. A single base deletion from the C1-inhibitor gene causes type I hereditary angio-oedema. Hum Hered. 1992;42(4):231–234. doi: 10.1159/000154075. [DOI] [PubMed] [Google Scholar]
  46. Siddique Z., McPhaden A. R., Whaley K. Type II hereditary angio-oedema associated with two mutations in one allele of the C1-inhibitor gene around the reactive-site coding region. Hum Hered. 1992;42(5):298–301. doi: 10.1159/000154086. [DOI] [PubMed] [Google Scholar]
  47. Sifers R. N., Brashears-Macatee S., Kidd V. J., Muensch H., Woo S. L. A frameshift mutation results in a truncated alpha 1-antitrypsin that is retained within the rough endoplasmic reticulum. J Biol Chem. 1988 May 25;263(15):7330–7335. [PubMed] [Google Scholar]
  48. Skriver K., Radziejewska E., Silbermann J. A., Donaldson V. H., Bock S. C. CpG mutations in the reactive site of human C1 inhibitor. J Biol Chem. 1989 Feb 25;264(6):3066–3071. [PubMed] [Google Scholar]
  49. Skriver K., Wikoff W. R., Patston P. A., Tausk F., Schapira M., Kaplan A. P., Bock S. C. Substrate properties of C1 inhibitor Ma (alanine 434----glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status. J Biol Chem. 1991 May 15;266(14):9216–9221. [PubMed] [Google Scholar]
  50. Stafford F. J., Bonifacino J. S. A permeabilized cell system identifies the endoplasmic reticulum as a site of protein degradation. J Cell Biol. 1991 Dec;115(5):1225–1236. doi: 10.1083/jcb.115.5.1225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Stoppa-Lyonnet D., Duponchel C., Meo T., Laurent J., Carter P. E., Arala-Chaves M., Cohen J. H., Dewald G., Goetz J., Hauptmann G. Recombinational biases in the rearranged C1-inhibitor genes of hereditary angioedema patients. Am J Hum Genet. 1991 Nov;49(5):1055–1062. [PMC free article] [PubMed] [Google Scholar]
  52. Stoppa-Lyonnet D., Tosi M., Laurent J., Sobel A., Lagrue G., Meo T. Altered C1 inhibitor genes in type I hereditary angioedema. N Engl J Med. 1987 Jul 2;317(1):1–6. doi: 10.1056/NEJM198707023170101. [DOI] [PubMed] [Google Scholar]
  53. Tosi M., Duponchel C., Bourgarel P., Colomb M., Meo T. Molecular cloning of human C1 inhibitor: sequence homologies with alpha 1-antitrypsin and other members of the serpins superfamily. Gene. 1986;42(3):265–272. doi: 10.1016/0378-1119(86)90230-1. [DOI] [PubMed] [Google Scholar]
  54. Tsao Y. S., Ivessa N. E., Adesnik M., Sabatini D. D., Kreibich G. Carboxy terminally truncated forms of ribophorin I are degraded in pre-Golgi compartments by a calcium-dependent process. J Cell Biol. 1992 Jan;116(1):57–67. doi: 10.1083/jcb.116.1.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Turner J. M., Brodsky M. H., Irving B. A., Levin S. D., Perlmutter R. M., Littman D. R. Interaction of the unique N-terminal region of tyrosine kinase p56lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs. Cell. 1990 Mar 9;60(5):755–765. doi: 10.1016/0092-8674(90)90090-2. [DOI] [PubMed] [Google Scholar]
  56. Verpy E., Biasotto M., Meo T., Tosi M. Efficient detection of point mutations on color-coded strands of target DNA. Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1873–1877. doi: 10.1073/pnas.91.5.1873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Virtanen I., Ekblom P., Laurila P. Subcellular compartmentalization of saccharide moieties in cultured normal and malignant cells. J Cell Biol. 1980 May;85(2):429–434. doi: 10.1083/jcb.85.2.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Wikström L., Lodish H. F. Endoplasmic reticulum degradation of a subunit of the asialoglycoprotein receptor in vitro. Vesicular transport from endoplasmic reticulum is unnecessary. J Biol Chem. 1992 Jan 5;267(1):5–8. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES